Impax Laboratories, Inc. (IPXL)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

30831 HUNTWOOD AVENUE HAYWARD, CA 94544

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. In the generic pharmaceuticals market, the Company focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system (CNS), disorders. Its brand-name product portfolio consists of development-stage projects to which it is applying its formulation and development expertise to develop differentiated, modified, or controlled-release versions of marketed drug substances. The Company operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceutical Division (Impax Division).

View SEC Filings from IPXL instead.
Q2 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 0 0 0 (0.0%) 0 (0.0%)
Funds Holding: 0 0 0 (0.0%) 0 (0.0%)
13F shares: 0 0 0 0
% Ownership
New Positions:
Increased Positions
Closed Positions
Reduced Positions
Total Calls 0 0
Total Puts 0 0
PUT/CALL Ratio
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding IPXL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IPXL BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SCHLOSSBERG MARK A SVP AND GENERAL COUNSEL

  • Officer
No longer subject to file 2018-05-04 0

BENET LESLIE Z

  • Director
No longer subject to file 2018-05-04 0

NESTOR MICHAEL PRESIDENT, IMPAX SPECIALTY

  • Officer
No longer subject to file 2018-05-04 0

CHAO ALLEN

  • Director
No longer subject to file 2018-05-04 0

BURR ROBERT L

  • Director
No longer subject to file 2018-05-04 0

TERRERI PETER R

  • Director
No longer subject to file 2018-05-04 0

REASONS BRYAN M. CHIEF FINANCIAL OFFICER

  • Officer
No longer subject to file 2018-05-04 0

PENDERGAST MARY K

  • Director
No longer subject to file 2018-05-04 0

NORNHOLD JEFFREY SVP, TECHNICAL OPERATIONS

  • Officer
No longer subject to file 2018-05-04 0

VERGIS JANET S.

  • Director
No longer subject to file 2018-05-04 0

BOOTHE DOUGLAS PRESIDENT, GENERICS DIVISION

  • Officer
No longer subject to file 2018-05-04 0

BUCHI J KEVIN

  • Director
No longer subject to file 2018-05-04 0

BISARO PAUL PRESIDENT AND CEO

  • Officer
  • Director
No longer subject to file 2018-05-04 0

BIERLY RICK

  • Director
9,270 2017-05-16 0

WILKINSON GEORGE FRED CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
464,862 2016-04-29 0

FLEMING NIGEL

  • Director
8,200 2015-08-31 0

MARKBREITER MICHAEL

  • Director
8,200 2015-08-28 0

HSU LARRY

  • Director
2,886,448 2015-05-12 0

BEN-MAIMON CAROLE PRESIDENT, GLOBAL PHARM.

  • Officer
85,914 2014-05-14 0

KOCH ARTHUR A JR EVP, FINANCE, AND CFO

  • Officer
142,415 2012-05-26 0

HILDENBRAND CHARLES V SVP, OPERATIONS

  • Officer
35,222 2011-05-26 0

MENGLER CHRISTOPHER

  • FORMER DIVISION PRESIDENT
No longer subject to file 2010-11-05 0

OH KIM SUN

  • Director
30,679 2009-11-11 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments